Icosavax, Inc. announced positive topline interim results from its Phase 1/1b clinical trial of IVX-121, a VLP displaying a prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen, in young and older adults. IVX-121 Phase 1/1b Trial Design: The Phase 1/1b clinical trial of IVX-121 is a randomized, observer-blinded, placebo-controlled, multi-center study designed to evaluate the safety and immunogenicity of three dose levels of IVX-121, with and without aluminum hydroxide adjuvant, in healthy young and older adults. The Phase 1 part of the trial enrolled 90 healthy young adults aged 18-45 years.

The Phase 1b part of the trial enrolled 130 healthy older adults aged 60-75 years. Subjects were administered a single dose of IVX-121 at one of three dose levels (25, 75, 250 µg), with or without aluminum hydroxide adjuvant, or placebo. The primary outcomes of the study were safety and immunogenicity up to 28 days post-vaccination; neutralizing antibodies to RSV-A and RSV-B were measured in international units (IU/mL) using the WHO international reference standard.

The trial was intended to inform the dose of IVX-121 to be evaluated in combination with Icosavax's hMPV VLP in an upcoming Phase 1 clinical trial of the company's RSV/hMPV bivalent vaccine candidate IVX-A12. Topline Results: Safety: In this Phase 1/1b study, IVX-121 was generally well-tolerated across all dosage groups: Solicited local and systemic adverse events (AEs) were generally mild or moderate, without dose-limiting reactogenicity; In the older adult target population, across the six dosage groups for IVX-121 with or without adjuvant, the proportion of subjects experiencing any systemic AE within seven days was 11-33%, and similar to 21% for placebo; The most common local and systemic AEs were injection site tenderness, headache and fatigue; There were no serious AEs related to vaccine, AEs of special interest, or AEs leading to discontinuation. Immunogenicity: In this Phase 1/1b study, IVX-121 induced a robust immune response in both young and older adult groups: The data indicated a dose-independent response, including at the lowest non-adjuvanted dose (25 µg); No additional benefit from the aluminum hydroxide adjuvant was observed at any dosage level in either portion of the study; Geometric mean titers for RSV-A and RSV-B were in comparable ranges for both groups; Young Adults (Phase 1): In young adults, across dosage groups, IVX-121 induced Geometric Mean Titers (GMTs) in RSV-A neutralizing antibodies (nAbs) of up to 7,687 IU/mL compared to 1,100 IU/mL for placebo at Day 28; These titers corresponded to a Geometric Mean Fold Rise (GMFR) versus baseline up to 10-fold for IVX-121 at Day 28.

Older Adults (Phase 1b): GMT responses in IU/mL for older adults were comparable with those for young adults; Across dosage groups, IVX-121 induced GMTs in RSV-A nAbs of up to 7,561 IU/mL compared to 1,692 IU/mL for placebo at Day 28; GMFR at Day 28 was up to 6-fold, reflecting higher baseline titers in the older adults group.